Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Illumina $500 million notes offering
We advised the underwriters on the offering
Olema Pharmaceuticals $218.5 million follow-on offering
We advised the underwriters on the offering
Bristol Myers Squibb $7 billion cash tender offer
We advised the dealer managers on the tender offer
Inventiva $172.5 million follow-on offering
We advised the underwriters on the offering
Ionis Pharmaceuticals $770 million convertible senior notes offering
We advised the representatives of the initial purchasers on the offering
GRAIL $300 million at-the-market offering
We advised the sales agents on the offering
Novartis $6 billion notes offering
We advised Novartis on the investment-grade debt offering
Novanta $632.5 million tangible equity units offering
We advised the representatives of the several underwriters on the offering
Bristol Myers Squibb €5 billion notes offering
We advised the underwriters on Bristol Myers Squibb Ireland’s inaugural euro issuance
Auna $400 million refinancing
We advised Auna on the transaction